ImmunoGen Investor Relations Material
Latest events
Q3 2023
ImmunoGen
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ImmunoGen Inc
Access all reports
ImmunoGen, Inc., is a clinical-stage biotechnology company. The company develops antibody-drug conjugate therapies to treat cancer. Its ADC product candidates include Binimetinib, an ADC designed to treat non-small cell lung cancer, colorectal cancer, and pancreatic cancer; Daratumumab, an ADC designed to treat multiple myeloma; and SAR302503, an ADC that combines trastuzumab with an anthracycline. The company's ADC product candidates are currently in various stages of clinical development. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
IMGN
Country
🇺🇸 United States